Article
Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.
Cancer prevention research (Philadelphia, Pa.) - 5 Jul 2023
Harper Diane M, Anderson Rye J, Baker Ed, Yu Tiffany M
Abstract excerpt
The first biomarker-based cervical cancer screening test, p16/Ki-67 dual-stained cytology (DS), has been clinically validated and approved in the United States for triage of women being screened for cervical cancer who test positive for high-risk human papillomavirus (hrHPV). The primary aim of this work is to evaluate the cost-effectiveness of DS triage after co-testing findings of positive non-16/18 HPV types...
Topics
Join the communities discussing this publication.
